Fairmount Funds Management LLC - 09 Feb 2026 Form 4 Insider Report for Galecto, Inc. (GLTO)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: GLTO
Reported as of: 09 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 12 Feb 2026, 06:03:41 UTC
Prior SEC filing: 22 Jan 2026
Next SEC filing: 25 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Tomas Kiselak, Managing Member of Fairmount Funds Management LLC

Key filing fact

Fairmount Funds Management LLC filed Form 4 for Galecto, Inc. (GLTO) on 12 Feb 2026.

Key facts

This page summarizes Fairmount Funds Management LLC's Form 4 filing for Galecto, Inc. (GLTO).
4 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 12 Feb 2026, 06:03.

Change

Previous filing in this sequence was filed on 22 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (5)

CIK 0001802528 Primary reporting owner

Fairmount Funds Management LLC

Relationship: Director, 10%+ Owner
Address: 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN
Signature: /s/ Tomas Kiselak, Managing Member of Fairmount Funds Management LLC
Signature date: 12 Feb 2026

CIK 0001769651

Fairmount Healthcare Fund II L.P.

Relationship: 10%+ Owner
Address: 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN
Signature: /s/ Tomas Kiselak, Managing Member of Fairmount Healthcare Fund II L.P.
Signature date: 12 Feb 2026

CIK 0002091559

Fairmount Healthcare Co-Invest V L.P.

Relationship: 10%+ Owner
Address: 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN
Signature: /s/ Tomas Kiselak, Managing Member of Fairmount Healthcare Co-Invest V L.P.
Signature date: 12 Feb 2026

CIK 0001830177

Kiselak Tomas

Relationship: 10%+ Owner
Address: 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN
Signature: /s/ Tomas Kiselak
Signature date: 12 Feb 2026

CIK 0001663607

Harwin Peter Evan

Relationship: Director, 10%+ Owner
Address: 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN
Signature: /s/ Peter Harwin
Signature date: 12 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

GLTO transaction

Common Stock

Options Exercise

Transaction value: $0
Shares: +5,809,000
Change %
Price: $0.000000
Shares after: 5,809,000
Date: 09 Feb 2026
Ownership: By Fairmount Healthcare Fund II L.P.
Footnotes: F1, F2, F3

GLTO transaction

Common Stock

Options Exercise

Transaction value: $0
Shares: +2,904,000
Change %
Price: $0.000000
Shares after: 2,904,000
Date: 09 Feb 2026
Ownership: By Fairmount Healthcare Co-Invest V L.P.
Footnotes: F1, F2, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

GLTO transaction Derivative

Series C Preferred Stock

Options Exercise

Transaction value: $0
Shares: -5,809
Change %: -83%
Price: $0.000000
Shares after: 1,148
Date: 09 Feb 2026
Ownership: By Fairmount Healthcare Fund II L.P.
Underlying class: Common Stock
Underlying amount: 5,809,000
Exercise price
Footnotes: F1, F2, F3, F4

GLTO transaction Derivative

Series C Preferred Stock

Options Exercise

Transaction value: $0
Shares: -2,904
Change %: -83%
Price: $0.000000
Shares after: 574
Date: 09 Feb 2026
Ownership: By Fairmount Healthcare Co-Invest V L.P.
Underlying class: Common Stock
Underlying amount: 2,904,000
Exercise price
Footnotes: F1, F2, F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

On February 9, 2026, the Issuer's stockholders approved the issuance of Common Stock upon conversion of the Issuer's Series C Non-Voting Convertible Preferred Stock, par value $0.00001 per share ("Series C Preferred Stock") (the "Requisite Stockholder Approval"). Accordingly, pursuant to the terms of the Certificate of Designations of Preferences, Rights and Limitations of Series C Non-Voting Convertible Preferred Stock, 5,809 shares of Series C Preferred Stock held by Fairmount Healthcare Fund II LP ("Fund II") and 2,904 shares of Series C Preferred Stock held by Fairmount Healthcare Co-Invest V L.P. ("Co-Invest") were converted into 5,809,000 shares of Common Stock and 2,904,000 shares of Common Stock, respectively. The securities of the Issuer held by the Reporting Persons, including the shares of Common Stock received upon conversion of the Series C Preferred Stock, are subject to the terms a lock-up agreement entered into with the underwriters for the Issuer's public offering,

Footnote F2

(Continued from footnote 1) pursuant to which certain of the Reporting Persons agreed, subject to certain exceptions, not to directly or indirectly sell or otherwise transfer securities of the Issuer for a period of 60 days following the date of the final prospectus supplement relating to the public offering, which was February 10, 2026.

Footnote F3

Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fund II and Co-Invest. Peter Harwin and Tomas Kiselak are the managers of Fairmount. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

Footnote F4

Following receipt of the Requisite Stockholder Approval, each share of Series C Preferred Stock automatically converted into 1,000 shares of Common Stock, subject to certain beneficial ownership limitations. The Series C Preferred Stock has no expiration date. Fairmount may not convert such shares if Fairmount, together with its affiliates, would beneficially own more than 19.99% of the number of shares of Common Stock outstanding immediately after giving effect to such conversion.

SEC remarks

Fairmount, Fund II and Co-Invest may each be deemed a director by deputization of the Issuer by virtue of the fact that Peter Harwin serves on the board of directors of the Issuer and is a manager of Fairmount.